Fosun Pharma subsidiary gets approval for drug clinical trial

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. [HKEX:2196] announced that its subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its drug, CMC-2310 Oral Soluble Film. The drug is intended for treating schizophrenia in adult and pediatric patients aged 13 years and older. As of March 2025, the group had invested approximately RMB 7.25 million in the research and development of CMC-2310. This same active ingredient was approved for marketing in China (excluding Hong Kong, Macau and Taiwan) in 2024. The announcement cautions investors regarding the risks inherent in the R&D of new drugs, noting the potential for clinical trial termination due to safety or efficacy concerns.